Mary Pan has been appointed vice president, Asia Pacific, ICON, where she will lead growth and expansion in the region. Also, Hiroshi Ichikawa has been appointed vice president and general manager of ICON’s operations in Japan.
 
Ms. Pan brings more than 15 years of global pharmaceutical and clinical development expertise. Previously she was head of strategy and innovation in Asia for Becton Dickinson. She also served as managing director, Asia-Pacific, for ClinTec International and held senior medical affairs and clinical development roles in Crucell (Johnson & Johnson) and Pfizer.
 
Mr. Ichikawa has 30 years of CRO and pharmaceutical industry experience in Japan. Previously, he served as executive vice president and senior director of the Regulatory Science Department at A2Healthcare Corp. He was also president and chief executive officer of Asklep Inc. following its acquisition of PPCJ Corp., a CRO he founded in 2008.   
 
Dr. Nuala Murphy, president, ICON Clinical Research Services, said, “Asia-Pacific continues to be an important region for our clients and we are committed to growing our presence and enhancing our capabilities in the region. I’m delighted to welcome Mary and Ichikawa-san to the leadership team in Asia. Their strong knowledge of the Asian clinical development landscape, coupled with their demonstrated leadership in growing successful operations in Asia, will be invaluable as we look to expand in this important region.”
 
ICON operates from 22 offices in Asia-Pacific and employs more than 2,600 professionals in the region. ICON’s presence and capabilities in Japan, in particular in oncology, were strengthened in 2014 through the acquisition of Aptiv Solutions, which included Japanese CRO, Niphix.